Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Подходы к терапии рецидивов и рефрактерных форм анапластической крупноклеточной лимфомы у детей и подростков: обзор литературы
Подходы к терапии рецидивов и рефрактерных форм анапластической крупноклеточной лимфомы у детей и подростков: обзор литературы
Волкова А.С. Подходы к терапии рецидивов и рефрактерных форм анапластической крупноклеточной лимфомы у детей и подростков: обзор литературы. Современная Онкология. 2024;26(4):404–408. DOI: 10.26442/18151434.2024.4.202906
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Использование риск-адаптированных программ химиотерапии в лечении анапластической крупноклеточной лимфомы (АККЛ) у детей и подростков позволило достичь относительно удовлетворительных показателей общей (80–85%) и бессобытийной (70–75%) выживаемости. Тем не менее рецидивы развиваются у 20–40% больных. Единая стратегия терапии 2-й линии в случае рефрактерного течения заболевания или рецидива (р/р) не определена, поэтому анализ возможных терапевтических опций для больных c р/р АККЛ является актуальной научно-практической задачей. В обзоре отражены данные научных публикаций из медицинских информационных ресурсов PubMed и Elibrary, включая клинические случаи, оригинальные научные исследования и литературные обзоры. Представлены современные опции лечения р/р АККЛ: интенсивная блоковая терапия с последующей трансплантацией аллогенных гемопоэтических стволовых клеток, таргетная, иммуно- и CAR-T-терапия.
Ключевые слова: анапластическая крупноклеточная лимфома, рецидив, рефрактерное течение, ALK, CD30, брентуксимаб ведотин, PD-L1, ниволумаб, трансплантация аллогенных гемопоэтических стволовых клеток
Keywords: anaplastic large cell lymphoma, relapse, refractory, ALK, CD30, brentuximab vedotin, PD-L1, nivolumab, allogeneic stem cell transplantation
Ключевые слова: анапластическая крупноклеточная лимфома, рецидив, рефрактерное течение, ALK, CD30, брентуксимаб ведотин, PD-L1, ниволумаб, трансплантация аллогенных гемопоэтических стволовых клеток
________________________________________________
Keywords: anaplastic large cell lymphoma, relapse, refractory, ALK, CD30, brentuximab vedotin, PD-L1, nivolumab, allogeneic stem cell transplantation
Полный текст
Список литературы
1. Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013;30:509-19.
2. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-95.
3. Валиев Т.Т. Современная стратегия диагностики и лечения неходжкинских лимфом у детей: aвтореф. дис. … д-ра мед. наук. М., 2014 [Valiev TT. Sovremennaia strategiia diagnostiki i lecheniia nekhodzhkinskikh limfom u detei: avtoref. dis. … d-ra med. nauk. Moscow, 2014 (in Russian)].
4. Валиев Т.Т., Морозова О.В., Ковригина А.М., и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012;57(1):3-9 [Valiev TT, Morozova OV, Kovrigina AM, et al. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Gematologiia i Transfuziologiia. 2012;57(1):3-9 (in Russian)].
5. Montes-Mojarro IA, Steinhilber J, Bonzheim I, et al. The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). Cancers (Basel). 2018;10(4):107. DOI:10.3390/cancers10040107
6. Lamant L, McCarthy K, d’Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-76. DOI:10.1200/JCO.2011.36.5411
7. Валиев Т.Т., Ковригина А.М. Неходжкинские лимфомы у детей и подростков. Руководство для врачей. М. 2024 [Valiev TT, Kovrigina AM. Nekhodzhkinskiie limfomy u detei i podrostkov. Rukovodstvo dlia vrachei. Moscow. 2024 (in Russian)].
8. Валиев Т.Т., Махонова Л.А., Ковригина А.М., и др. Случай врожденного лангергансоклеточного гистиоцитоза у ребенка раннего возраста. Онкогематология.
2011;6(2):19-23 [Valiev TT, Makhonova LA, Kovrigina AM, et al. Case of congenital Langerhans cells histiocytosis in an infant. Oncohematology. 2011;6(2):19-23 (in Russian)].
9. Prokoph N, Larose H, Lim MS, et al. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers (Basel). 2018;10(4):99. DOI:10.3390/cancers10040099
10. Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120-42. DOI:10.3960/jslrt.17023
11. Falini B, Pileri S, Zinzani PL, et al. ALK+ Lymphoma: Clinico-Pathological Findings and Outcome. Blood. 1999;93:2697-706.
12. Trivedi M, Thankamony P, Nair M, et al. Clinical profile and outcome of children with anaplastic large cell lymphoma treated with short-course chemotherapy – ten years’ experience from a tertiary care center in a LMIC. Pediatr Hematol Oncol. 2023;40(5):485-96. DOI:10.1080/08880018.2023.2212710
13. Han JY, Suh JK, Lee SW, et al. Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood Res. 2014;49(4):246-52. DOI:10.5045/br.2014.49.4.246
14. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-7. DOI:10.1200/JCO.2005.11.075
15. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-706. DOI:10.1182/blood.v97.12.3699
16. Барях Е.А., Кременецкая А.М., Кравченко С.К., и др. Новый короткий высокоинтенсивный протокол терапии беркиттоподобной лимфомы взрослых БПЛ-М-04: промежуточные результаты. Гематология и трансфузиология. 2006;51(6):3-11 [Bariakh EA, Kremenetskaia AM, Kravchenko SK, et al. Novyi korotkii vysokointensivnyi protokol terapii berkittopodobnoi limfomy vzroslykh BPL-M-04: promezhutochnye rezultaty. Gematologiia i Transfuziologiia. 2006;51(6):3-11 (in Russian)].
17. Mussolin L, Le Deley MC, Carraro E, et al. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020;12(10):2747. DOI:10.3390/cancers12102747
18. Noguchi K, Ikawa Y. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. Cancers. 2023;15:5733. DOI:10.3390/cancers15245733
19. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065-71. DOI:10.1200/JCO.2011.34.8417
20. Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056-61. DOI:10.1200/JCO.2008.20.1764
21. Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-61. DOI:10.1016/S2352-3026(18)30153-4
22. Мякова Н.В., Евстратов Д.А., Абрамов Д.С., и др. Применение брентуксимаба ведотина у детей и подростков с лимфомой Ходжкина и анапластической крупноклеточной лимфомой – обзор литературы и собственные наблюдения. Онкогематология. 2016;11(1):8-13 [Myakova NV, Evstratov DA, Abramov DS, et al. Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience. Oncohematology. 2016;11(1):8-13 (in Russian)].
DOI:10.17650/1818-8346-2016-11-1-8-13
23. Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol. 2017;35(28):3215-21. DOI:10.1200/JCO.2017.73.4830
24. Knörr F, Schellekens KPJ, Schoot RA, et al. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica. 2023;108(5):1442-6. DOI:10.3324/haematol.2022.281896
25. Yang J, Li J, Gu WY, et al. Central Nervous System Relapse in a Pediatric Anaplastic Large Cell Lymphoma Patient with CLTC/ALK Translocation Treated with Alectinib: A Case Report. World J Clin Cases. 2020;8:1685-92. DOI:10.12998/wjcc.v8.i9.1685
26. Richly H, Kim TM, Schuler M, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood. 2015;126(10):1257-8. DOI:10.1182/blood-2014-12-617779
27. Knörr F, Brugières L, Pillon M, et al. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020;38(34):3999-4009. DOI:10.1200/JCO.20.00157
28. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-603. DOI:10.1182/blood.2020009806
29. Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016;374(1):95-6. DOI:10.1056/NEJMc1511045
30. Ruf S, Hebart H, Hjalgrim LL, et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. Pediatr Blood Cancer. 2018;65(6):e27003. DOI:10.1002/pbc.27003
31. Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020;111(12):4540-7. DOI:10.1111/cas.14671
32. Галимов А.Н., Лепик Е.Е., Козлов А.В., и др. Лечение рецидивирующей и рефрактерной анапластической крупноклеточной лимфомы, экспрессирующей киназу анапластической лимфомы: опыт одного Центра. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023;22(1):22-31 [Galimov AN, Lepik EE, Kozlov AV, et al. The treatment of relapsed/refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience. Pediatric Hematology/Oncology and Immunopathology. 2023;22(1):22-31 (in Russian)]. DOI:10.24287/1726-1708-2023-22-1-22-31
33. Hare L, Burke GAA, Turner SD. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers (Basel). 2021;13(23):6003. DOI:10.3390/cancers13236003
34. Rigaud C, Abbou S, Minard-Colin V, et al. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65(4). DOI:10.1002/pbc.26902
35. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176-82. DOI:10.1111/j.1365-2141.2006.06004.x
36. Kozlov AV, Valiev TT, Uldasheva SA, et al. Successful treatment of relapsed/refractory anaplastic large cell lymphoma in adolescent patient: a case report. Cell Ther Transplant. 2022;11(3-4):77-82.
37. Yang J, Yang X, Liu Y, et al. A novel and successful patient or donor-derived CD7-targeted CAR T-cell therapy for relapsed or refractory T-cell lymphoblastic lymphoma (R/R T-LBL). Blood. 2021;138:652.
38. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-44.
39. Frigault MJ, Chen Y-B, Gallagher KME, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood. 2021;138:653.
40. Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127:3462-71.
41. Mu W, Zhang M, Hu G, et al. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Front Immunol. 2023;14:1280007. DOI:10.3389/fimmu.2023.1280007
2. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-95.
3. Valiev TT. Sovremennaia strategiia diagnostiki i lecheniia nekhodzhkinskikh limfom u detei: avtoref. dis. … d-ra med. nauk. Moscow, 2014 (in Russian).
4. Valiev TT, Morozova OV, Kovrigina AM, et al. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Gematologiia i Transfuziologiia. 2012;57(1):3-9 (in Russian).
5. Montes-Mojarro IA, Steinhilber J, Bonzheim I, et al. The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). Cancers (Basel). 2018;10(4):107. DOI:10.3390/cancers10040107
6. Lamant L, McCarthy K, d’Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-76. DOI:10.1200/JCO.2011.36.5411
7. Valiev TT, Kovrigina AM. Nekhodzhkinskiie limfomy u detei i podrostkov. Rukovodstvo dlia vrachei. Moscow. 2024 (in Russian).
8. Valiev TT, Makhonova LA, Kovrigina AM, et al. Case of congenital Langerhans cells histiocytosis in an infant. Oncohematology. 2011;6(2):19-23 (in Russian).
9. Prokoph N, Larose H, Lim MS, et al. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers (Basel). 2018;10(4):99. DOI:10.3390/cancers10040099
10. Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120-42. DOI:10.3960/jslrt.17023
11. Falini B, Pileri S, Zinzani PL, et al. ALK+ Lymphoma: Clinico-Pathological Findings and Outcome. Blood. 1999;93:2697-706.
12. Trivedi M, Thankamony P, Nair M, et al. Clinical profile and outcome of children with anaplastic large cell lymphoma treated with short-course chemotherapy – ten years’ experience from a tertiary care center in a LMIC. Pediatr Hematol Oncol. 2023;40(5):485-96. DOI:10.1080/08880018.2023.2212710
13. Han JY, Suh JK, Lee SW, et al. Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood Res. 2014;49(4):246-52. DOI:10.5045/br.2014.49.4.246
14. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-7. DOI:10.1200/JCO.2005.11.075
15. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-706. DOI:10.1182/blood.v97.12.3699
16. Bariakh EA, Kremenetskaia AM, Kravchenko SK, et al. Novyi korotkii vysokointensivnyi protokol terapii berkittopodobnoi limfomy vzroslykh BPL-M-04: promezhutochnye rezultaty. Gematologiia i Transfuziologiia. 2006;51(6):3-11 (in Russian).
17. Mussolin L, Le Deley MC, Carraro E, et al. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020;12(10):2747. DOI:10.3390/cancers12102747
18. Noguchi K, Ikawa Y. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. Cancers. 2023;15:5733. DOI:10.3390/cancers15245733
19. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065-71. DOI:10.1200/JCO.2011.34.8417
20. Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056-61. DOI:10.1200/JCO.2008.20.1764
21. Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-61. DOI:10.1016/S2352-3026(18)30153-4
22. Myakova NV, Evstratov DA, Abramov DS, et al. Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience. Oncohematology. 2016;11(1):8-13 (in Russian). DOI:10.17650/1818-8346-2016-11-1-8-13
23. Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol. 2017;35(28):3215-21. DOI:10.1200/JCO.2017.73.4830
24. Knörr F, Schellekens KPJ, Schoot RA, et al. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica. 2023;108(5):1442-6. DOI:10.3324/haematol.2022.281896
25. Yang J, Li J, Gu WY, et al. Central Nervous System Relapse in a Pediatric Anaplastic Large Cell Lymphoma Patient with CLTC/ALK Translocation Treated with Alectinib: A Case Report. World J Clin Cases. 2020;8:1685-92. DOI:10.12998/wjcc.v8.i9.1685
26. Richly H, Kim TM, Schuler M, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood. 2015;126(10):1257-8. DOI:10.1182/blood-2014-12-617779
27. Knörr F, Brugières L, Pillon M, et al. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020;38(34):3999-4009. DOI:10.1200/JCO.20.00157
28. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-603. DOI:10.1182/blood.2020009806
29. Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016;374(1):95-6. DOI:10.1056/NEJMc1511045
30. Ruf S, Hebart H, Hjalgrim LL, et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. Pediatr Blood Cancer. 2018;65(6):e27003. DOI:10.1002/pbc.27003
31. Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020;111(12):4540-7. DOI:10.1111/cas.14671
32. Galimov AN, Lepik EE, Kozlov AV, et al. The treatment of relapsed/refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience. Pediatric Hematology/Oncology and Immunopathology. 2023;22(1):22-31 (in Russian). DOI:10.24287/1726-1708-2023-22-1-22-31
33. Hare L, Burke GAA, Turner SD. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers (Basel). 2021;13(23):6003. DOI:10.3390/cancers13236003
34. Rigaud C, Abbou S, Minard-Colin V, et al. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65(4). DOI:10.1002/pbc.26902
35. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176-82. DOI:10.1111/j.1365-2141.2006.06004.x
36. Kozlov AV, Valiev TT, Uldasheva SA, et al. Successful treatment of relapsed/refractory anaplastic large cell lymphoma in adolescent patient: a case report. Cell Ther Transplant. 2022;11(3-4):77-82.
37. Yang J, Yang X, Liu Y, et al. A novel and successful patient or donor-derived CD7-targeted CAR T-cell therapy for relapsed or refractory T-cell lymphoblastic lymphoma (R/R T-LBL). Blood. 2021;138:652.
38. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-44.
39. Frigault MJ, Chen Y-B, Gallagher KME, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood. 2021;138:653.
40. Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127:3462-71.
41. Mu W, Zhang M, Hu G, et al. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Front Immunol. 2023;14:1280007. DOI:10.3389/fimmu.2023.1280007
2. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-95.
3. Валиев Т.Т. Современная стратегия диагностики и лечения неходжкинских лимфом у детей: aвтореф. дис. … д-ра мед. наук. М., 2014 [Valiev TT. Sovremennaia strategiia diagnostiki i lecheniia nekhodzhkinskikh limfom u detei: avtoref. dis. … d-ra med. nauk. Moscow, 2014 (in Russian)].
4. Валиев Т.Т., Морозова О.В., Ковригина А.М., и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012;57(1):3-9 [Valiev TT, Morozova OV, Kovrigina AM, et al. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Gematologiia i Transfuziologiia. 2012;57(1):3-9 (in Russian)].
5. Montes-Mojarro IA, Steinhilber J, Bonzheim I, et al. The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). Cancers (Basel). 2018;10(4):107. DOI:10.3390/cancers10040107
6. Lamant L, McCarthy K, d’Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-76. DOI:10.1200/JCO.2011.36.5411
7. Валиев Т.Т., Ковригина А.М. Неходжкинские лимфомы у детей и подростков. Руководство для врачей. М. 2024 [Valiev TT, Kovrigina AM. Nekhodzhkinskiie limfomy u detei i podrostkov. Rukovodstvo dlia vrachei. Moscow. 2024 (in Russian)].
8. Валиев Т.Т., Махонова Л.А., Ковригина А.М., и др. Случай врожденного лангергансоклеточного гистиоцитоза у ребенка раннего возраста. Онкогематология.
2011;6(2):19-23 [Valiev TT, Makhonova LA, Kovrigina AM, et al. Case of congenital Langerhans cells histiocytosis in an infant. Oncohematology. 2011;6(2):19-23 (in Russian)].
9. Prokoph N, Larose H, Lim MS, et al. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers (Basel). 2018;10(4):99. DOI:10.3390/cancers10040099
10. Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120-42. DOI:10.3960/jslrt.17023
11. Falini B, Pileri S, Zinzani PL, et al. ALK+ Lymphoma: Clinico-Pathological Findings and Outcome. Blood. 1999;93:2697-706.
12. Trivedi M, Thankamony P, Nair M, et al. Clinical profile and outcome of children with anaplastic large cell lymphoma treated with short-course chemotherapy – ten years’ experience from a tertiary care center in a LMIC. Pediatr Hematol Oncol. 2023;40(5):485-96. DOI:10.1080/08880018.2023.2212710
13. Han JY, Suh JK, Lee SW, et al. Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood Res. 2014;49(4):246-52. DOI:10.5045/br.2014.49.4.246
14. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-7. DOI:10.1200/JCO.2005.11.075
15. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-706. DOI:10.1182/blood.v97.12.3699
16. Барях Е.А., Кременецкая А.М., Кравченко С.К., и др. Новый короткий высокоинтенсивный протокол терапии беркиттоподобной лимфомы взрослых БПЛ-М-04: промежуточные результаты. Гематология и трансфузиология. 2006;51(6):3-11 [Bariakh EA, Kremenetskaia AM, Kravchenko SK, et al. Novyi korotkii vysokointensivnyi protokol terapii berkittopodobnoi limfomy vzroslykh BPL-M-04: promezhutochnye rezultaty. Gematologiia i Transfuziologiia. 2006;51(6):3-11 (in Russian)].
17. Mussolin L, Le Deley MC, Carraro E, et al. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020;12(10):2747. DOI:10.3390/cancers12102747
18. Noguchi K, Ikawa Y. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. Cancers. 2023;15:5733. DOI:10.3390/cancers15245733
19. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065-71. DOI:10.1200/JCO.2011.34.8417
20. Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056-61. DOI:10.1200/JCO.2008.20.1764
21. Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-61. DOI:10.1016/S2352-3026(18)30153-4
22. Мякова Н.В., Евстратов Д.А., Абрамов Д.С., и др. Применение брентуксимаба ведотина у детей и подростков с лимфомой Ходжкина и анапластической крупноклеточной лимфомой – обзор литературы и собственные наблюдения. Онкогематология. 2016;11(1):8-13 [Myakova NV, Evstratov DA, Abramov DS, et al. Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience. Oncohematology. 2016;11(1):8-13 (in Russian)].
DOI:10.17650/1818-8346-2016-11-1-8-13
23. Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol. 2017;35(28):3215-21. DOI:10.1200/JCO.2017.73.4830
24. Knörr F, Schellekens KPJ, Schoot RA, et al. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica. 2023;108(5):1442-6. DOI:10.3324/haematol.2022.281896
25. Yang J, Li J, Gu WY, et al. Central Nervous System Relapse in a Pediatric Anaplastic Large Cell Lymphoma Patient with CLTC/ALK Translocation Treated with Alectinib: A Case Report. World J Clin Cases. 2020;8:1685-92. DOI:10.12998/wjcc.v8.i9.1685
26. Richly H, Kim TM, Schuler M, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood. 2015;126(10):1257-8. DOI:10.1182/blood-2014-12-617779
27. Knörr F, Brugières L, Pillon M, et al. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020;38(34):3999-4009. DOI:10.1200/JCO.20.00157
28. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-603. DOI:10.1182/blood.2020009806
29. Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016;374(1):95-6. DOI:10.1056/NEJMc1511045
30. Ruf S, Hebart H, Hjalgrim LL, et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. Pediatr Blood Cancer. 2018;65(6):e27003. DOI:10.1002/pbc.27003
31. Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020;111(12):4540-7. DOI:10.1111/cas.14671
32. Галимов А.Н., Лепик Е.Е., Козлов А.В., и др. Лечение рецидивирующей и рефрактерной анапластической крупноклеточной лимфомы, экспрессирующей киназу анапластической лимфомы: опыт одного Центра. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023;22(1):22-31 [Galimov AN, Lepik EE, Kozlov AV, et al. The treatment of relapsed/refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience. Pediatric Hematology/Oncology and Immunopathology. 2023;22(1):22-31 (in Russian)]. DOI:10.24287/1726-1708-2023-22-1-22-31
33. Hare L, Burke GAA, Turner SD. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers (Basel). 2021;13(23):6003. DOI:10.3390/cancers13236003
34. Rigaud C, Abbou S, Minard-Colin V, et al. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65(4). DOI:10.1002/pbc.26902
35. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176-82. DOI:10.1111/j.1365-2141.2006.06004.x
36. Kozlov AV, Valiev TT, Uldasheva SA, et al. Successful treatment of relapsed/refractory anaplastic large cell lymphoma in adolescent patient: a case report. Cell Ther Transplant. 2022;11(3-4):77-82.
37. Yang J, Yang X, Liu Y, et al. A novel and successful patient or donor-derived CD7-targeted CAR T-cell therapy for relapsed or refractory T-cell lymphoblastic lymphoma (R/R T-LBL). Blood. 2021;138:652.
38. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-44.
39. Frigault MJ, Chen Y-B, Gallagher KME, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood. 2021;138:653.
40. Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127:3462-71.
41. Mu W, Zhang M, Hu G, et al. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Front Immunol. 2023;14:1280007. DOI:10.3389/fimmu.2023.1280007
________________________________________________
2. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-95.
3. Valiev TT. Sovremennaia strategiia diagnostiki i lecheniia nekhodzhkinskikh limfom u detei: avtoref. dis. … d-ra med. nauk. Moscow, 2014 (in Russian).
4. Valiev TT, Morozova OV, Kovrigina AM, et al. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Gematologiia i Transfuziologiia. 2012;57(1):3-9 (in Russian).
5. Montes-Mojarro IA, Steinhilber J, Bonzheim I, et al. The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). Cancers (Basel). 2018;10(4):107. DOI:10.3390/cancers10040107
6. Lamant L, McCarthy K, d’Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-76. DOI:10.1200/JCO.2011.36.5411
7. Valiev TT, Kovrigina AM. Nekhodzhkinskiie limfomy u detei i podrostkov. Rukovodstvo dlia vrachei. Moscow. 2024 (in Russian).
8. Valiev TT, Makhonova LA, Kovrigina AM, et al. Case of congenital Langerhans cells histiocytosis in an infant. Oncohematology. 2011;6(2):19-23 (in Russian).
9. Prokoph N, Larose H, Lim MS, et al. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers (Basel). 2018;10(4):99. DOI:10.3390/cancers10040099
10. Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120-42. DOI:10.3960/jslrt.17023
11. Falini B, Pileri S, Zinzani PL, et al. ALK+ Lymphoma: Clinico-Pathological Findings and Outcome. Blood. 1999;93:2697-706.
12. Trivedi M, Thankamony P, Nair M, et al. Clinical profile and outcome of children with anaplastic large cell lymphoma treated with short-course chemotherapy – ten years’ experience from a tertiary care center in a LMIC. Pediatr Hematol Oncol. 2023;40(5):485-96. DOI:10.1080/08880018.2023.2212710
13. Han JY, Suh JK, Lee SW, et al. Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood Res. 2014;49(4):246-52. DOI:10.5045/br.2014.49.4.246
14. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541-7. DOI:10.1200/JCO.2005.11.075
15. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-706. DOI:10.1182/blood.v97.12.3699
16. Bariakh EA, Kremenetskaia AM, Kravchenko SK, et al. Novyi korotkii vysokointensivnyi protokol terapii berkittopodobnoi limfomy vzroslykh BPL-M-04: promezhutochnye rezultaty. Gematologiia i Transfuziologiia. 2006;51(6):3-11 (in Russian).
17. Mussolin L, Le Deley MC, Carraro E, et al. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020;12(10):2747. DOI:10.3390/cancers12102747
18. Noguchi K, Ikawa Y. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. Cancers. 2023;15:5733. DOI:10.3390/cancers15245733
19. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065-71. DOI:10.1200/JCO.2011.34.8417
20. Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056-61. DOI:10.1200/JCO.2008.20.1764
21. Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-61. DOI:10.1016/S2352-3026(18)30153-4
22. Myakova NV, Evstratov DA, Abramov DS, et al. Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience. Oncohematology. 2016;11(1):8-13 (in Russian). DOI:10.17650/1818-8346-2016-11-1-8-13
23. Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol. 2017;35(28):3215-21. DOI:10.1200/JCO.2017.73.4830
24. Knörr F, Schellekens KPJ, Schoot RA, et al. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica. 2023;108(5):1442-6. DOI:10.3324/haematol.2022.281896
25. Yang J, Li J, Gu WY, et al. Central Nervous System Relapse in a Pediatric Anaplastic Large Cell Lymphoma Patient with CLTC/ALK Translocation Treated with Alectinib: A Case Report. World J Clin Cases. 2020;8:1685-92. DOI:10.12998/wjcc.v8.i9.1685
26. Richly H, Kim TM, Schuler M, et al. Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood. 2015;126(10):1257-8. DOI:10.1182/blood-2014-12-617779
27. Knörr F, Brugières L, Pillon M, et al. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020;38(34):3999-4009. DOI:10.1200/JCO.20.00157
28. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-603. DOI:10.1182/blood.2020009806
29. Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016;374(1):95-6. DOI:10.1056/NEJMc1511045
30. Ruf S, Hebart H, Hjalgrim LL, et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. Pediatr Blood Cancer. 2018;65(6):e27003. DOI:10.1002/pbc.27003
31. Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci. 2020;111(12):4540-7. DOI:10.1111/cas.14671
32. Galimov AN, Lepik EE, Kozlov AV, et al. The treatment of relapsed/refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience. Pediatric Hematology/Oncology and Immunopathology. 2023;22(1):22-31 (in Russian). DOI:10.24287/1726-1708-2023-22-1-22-31
33. Hare L, Burke GAA, Turner SD. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers (Basel). 2021;13(23):6003. DOI:10.3390/cancers13236003
34. Rigaud C, Abbou S, Minard-Colin V, et al. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65(4). DOI:10.1002/pbc.26902
35. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176-82. DOI:10.1111/j.1365-2141.2006.06004.x
36. Kozlov AV, Valiev TT, Uldasheva SA, et al. Successful treatment of relapsed/refractory anaplastic large cell lymphoma in adolescent patient: a case report. Cell Ther Transplant. 2022;11(3-4):77-82.
37. Yang J, Yang X, Liu Y, et al. A novel and successful patient or donor-derived CD7-targeted CAR T-cell therapy for relapsed or refractory T-cell lymphoblastic lymphoma (R/R T-LBL). Blood. 2021;138:652.
38. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-44.
39. Frigault MJ, Chen Y-B, Gallagher KME, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood. 2021;138:653.
40. Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127:3462-71.
41. Mu W, Zhang M, Hu G, et al. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Front Immunol. 2023;14:1280007. DOI:10.3389/fimmu.2023.1280007
Авторы
А.С. Волкова*
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия
*anastasia.sergeevna.volkova@gmail.com
Blokhin National Medical Research Center of Oncology, Moscow, Russia
*anastasia.sergeevna.volkova@gmail.com
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия
*anastasia.sergeevna.volkova@gmail.com
________________________________________________
Blokhin National Medical Research Center of Oncology, Moscow, Russia
*anastasia.sergeevna.volkova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.